Holen Sie sich die Stockscreener-App
0.8159
0.27%
0.0022
Handel nachbörslich:
.78
-0.0359
-4.40%
Schlusskurs vom Vortag:
$0.8137
Offen:
$0.8113
24-Stunden-Volumen:
98,151
Relative Volume:
0.88
Marktkapitalisierung:
$6.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-0.0587
EPS:
-13.91
Netto-Cashflow:
$-13.75M
1W Leistung:
+15.19%
1M Leistung:
+3.20%
6M Leistung:
-41.72%
1J Leistung:
-78.53%
1-Tages-Spanne:
$0.8003
$0.8392
1-Wochen-Bereich:
$0.691
$0.84
52-Wochen-Spanne:
$0.65
$4.35
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Vergleichen Sie KTTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.8159 | 6.06M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Real time scanner hits for Pasithea Therapeutics Corp. Equity Warrant explained2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Chart based analysis of Pasithea Therapeutics Corp. Equity Warrant trendsJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Understanding Pasithea Therapeutics Corp. Equity Warrant’s price movementEarnings Overview Summary & Daily Profit Maximizing Tips - newser.com
Why retail investors pile into Pasithea Therapeutics Corp. Equity Warrant stockWeekly Investment Report & Free Risk Controlled Daily Trade Plans - newser.com
Backtesting results for Pasithea Therapeutics Corp. Equity Warrant trading strategies2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Does Pasithea Therapeutics Corp. Equity Warrant qualify in momentum factor screening2025 Analyst Calls & Growth Oriented Trading Recommendations - newser.com
Is Pasithea Therapeutics Corp. Equity Warrant stock positioned for long term growth2025 Market Outlook & Momentum Based Trading Signals - newser.com
Pasithea Therapeutics Corp. stock trend forecastStock Surge & AI Driven Price Predictions - newser.com
Will breakout in Pasithea Therapeutics Corp. lead to full recovery2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
Pasithea Therapeutics Corp.’s volatility index tracking explainedJuly 2025 Market Mood & AI Powered Market Entry Strategies - newser.com
What institutional flow reveals about Pasithea Therapeutics Corp. Equity Warrant2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Real time social sentiment graph for Pasithea Therapeutics Corp. Equity WarrantQuarterly Profit Summary & High Win Rate Trade Tips - newser.com
Will Pasithea Therapeutics Corp. stock outperform tech sector in 2025Short Setup & Smart Money Movement Alerts - newser.com
Automated trading signals detected on Pasithea Therapeutics Corp. Equity Warrant2025 EndofYear Setup & Trade Opportunity Analysis - newser.com
Is it too late to sell Pasithea Therapeutics Corp.July 2025 Update & Fast Entry High Yield Tips - newser.com
Comparing Pasithea Therapeutics Corp. Equity Warrant in custom built stock radarsJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
Can Pasithea Therapeutics Corp. Equity Warrant stock beat market expectations this quarterQuarterly Portfolio Summary & Community Consensus Trade Alerts - newser.com
Has Pasithea Therapeutics Corp. formed a bullish divergenceQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Is Pasithea Therapeutics Corp. stock cheap compared to fundamentalsEarnings Recap Summary & Daily Stock Momentum Reports - newser.com
Pasithea Therapeutics Corp. Equity Warrant stock daily chart insightsJuly 2025 Breakouts & Safe Swing Trade Setups - newser.com
Is Pasithea Therapeutics Corp. stock a dividend growth opportunityJuly 2025 Sector Moves & Growth Focused Stock Reports - newser.com
Is Pasithea Therapeutics Corp. stock a safe investment in uncertain marketsTreasury Yields & Weekly Market Pulse Updates - newser.com
Will Pasithea Therapeutics Corp. Equity Warrant stock outperform value stocksJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
Is Pasithea Therapeutics Corp. stock a buy for dividend growthEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Why Pasithea Therapeutics Corp. Equity Warrant stock is trending among retail tradersJuly 2025 Levels & Reliable Breakout Forecasts - newser.com
Has Pasithea Therapeutics Corp. Equity Warrant found a price floorJuly 2025 Action & Community Consensus Picks - newser.com
Can Pasithea Therapeutics Corp. stock outperform in 2025 bull marketDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Will Pasithea Therapeutics Corp. Equity Warrant stock continue dividend increasesMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Short interest data insights for Pasithea Therapeutics Corp.Quarterly Investment Review & Reliable Breakout Forecasts - newser.com
Why Pasithea Therapeutics Corp. stock is favored by top institutionsJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
Applying sector rotation models to Pasithea Therapeutics Corp. Equity WarrantJuly 2025 Patterns & Safe Entry Momentum Tips - newser.com
Can Pasithea Therapeutics Corp. stock attract ESG capital inflowsEntry Point & Community Verified Trade Signals - newser.com
Is Pasithea Therapeutics Corp. reversing from oversold territory2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
What earnings revisions data tells us about Pasithea Therapeutics Corp.Treasury Yields & AI Powered Market Entry Strategies - newser.com
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):